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Abstract
Histone deacetylase 2 (HDAC2) is crucial for embryonic development, affects cytokine signaling relevant for immune
responses and is often significantly overexpressed in solid tumors; but little is known about its role in human hepatocellular
carcinoma (HCC). In this study, we showed that targeted-disruption of HDAC2 resulted in reduction of both tumor cell
growth and de novo DNA synthesis in Hep3B cells. We then demonstrated that HDAC2 regulated cell cycle and that
disruption of HDAC2 caused G1/S arrest in cell cycle. In G1/S transition, targeted-disruption of HDAC2 selectively induced
the expression of p16
INK4A and p21
WAF1/Cip1, and simultaneously suppressed the expression of cyclin D1, CDK4 and CDK2.
Consequently, HDAC2 inhibition led to the down-regulation of E2F/DP1 target genes through a reduction in
phosphorylation status of pRb protein. In addition, sustained suppression of HDAC2 attenuated in vitro colony formation
and in vivo tumor growth in a mouse xenograft model. Further, we found that HDAC2 suppresses p21
WAF1/Cip1
transcriptional activity via Sp1-binding site enriched proximal region of p21
WAF1/Cip1 promoter. In conclusion, we suggest
that the aberrant regulation of HDAC2 may play a pivotal role in the development of HCC through its regulation of cell cycle
components at the transcription level providing HDAC2 as a relevant target in liver cancer therapy.
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Introduction
Acetylation of histones and non-histone proteins pivotally
modulates gene expression and cell signaling. Histone deacetylases
(HDACs), which remove acetyl groups from hyper-acetylated
histones, counteract the effects of histone acetyltransferases
(HATs) and return histone to its basal state with the concomitant
suppression of gene transcription. There are 18 HDACs which are
generally divided into four classes based on sequence homo-
logy to yeast counterparts [1,2]. There is clear evidence for the
involvement of both HATs and HDACs in cell proliferation,
differentiation and cell cycle regulation [3,4]. Moreover, it has been
reported that the pathological activity and deregulation of HDACs
can lead to several diseases such as cancer, immunological
disturbances and muscular dystrophies [2,5].A multitude of HDAC
inhibitors have been developed and are currently tested as
anticancer agents in various solid and hematologic malignancies.
However, the HDAC inhibitors used to demonstrate effects on cells
are for the most part non-specific for the different HDAC isoforms
[6]. In addition, although there are clear evidences for the
involvement of HDACs in the development of cancer, the specific
roles of individual HDAC in the regulation of cell proliferation and
apoptosis are unclear.
A previous study has suggested that HDAC2 expression was
increased by the loss of APC in human colorectal cancer [7]. We
have also reported that overexpression of HDAC2 was found in
stomach and liver cancer [8,9]. Moreover, we have noted that
HDAC2 expression was gradually increased from non-tumor to
overt cancer based on gene expression analysis of multi-step
histopathological grades of HCC (Figure S1) [10]. These results
suggest that HDAC2 plays an important role in the development
and progression of those cancers. In fact, there were some re-
ports suggesting that inhibition of HDACs using various known
HDAC inhibitors exhibited antitumor activities and/or apoptot-
ic effects in HCC model systems including HCC-derived cell
lines or murine models [11,12]. Furthermore, a recent report
suggested that HDAC inhibitor enhanced the sensitivity towards
cell death-mediated apoptosis such as TNF-related apoptosis
inducing ligand [13]. However, the underlying molecular
mechanisms of HDAC inhibition in HCC remain largely
unknown. Also, no attempts have been made so far to explain
the cellular mechanisms responsible for the mitogenic potential of
HDAC2 in HCC.
In the present study, to investigate biological roles of HDAC2
that confer oncogenic potential in human HCC, we assessed the
aberrant regulation of HDAC2 in human HCC and examined the
regulatory mechanisms of HDAC2 in cell cycle of HCC cells. In
addition, in vitro and in vivo experimental tumorigenic potential of
HDAC2 were explored using stable HDAC2 knockdown cell
lines.
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Aberrant regulation of HDAC2 is independent of Wnt
pathway and c-Myc in HCC
A previous study demonstrated that the increased HDAC2
expression was found in colon cancer, and the induction of
HDAC2 was dependent on Wnt pathway and c-Myc [7]. Our
previous report also showed the overexpression of HDAC2 in
human HCCs [8,10]. It has been reported that activation of Wnt
pathway in hepatocarcinogenesis can be caused by a stabilizing
mutation of b-catenin gene (15,25% of cases) or by an inactivating
mutation of Axin1 gene (5% of cases) [14]. This fact raises a
possibility that increased HDAC2 expression could also be
regulated by Wnt pathway in HCC progression.
Thus, to identify the aberrant expression of HDAC2 and
correlate its regulation with Wnt pathway, we performed immuno-
blotting of HDAC2, b-catenin, cyclin D1 and c-Myc in a subset of
10 pairedhuman HCCs.Asshown inFigure1A, HDAC2appeared
to be highly overexpressed in all 10 HCC tissues compared to the
corresponding non-cancerous tissues. However, up-regulation of b-
catenin was observed in 3 cases (patient# 1, 5 and 7) out of the 10
examined HCCs. Thisfrequency of b-catenin overexpression (30%)
is consistent with previous reports on the activation of Wnt signaling
by stabilization of b-catenin in HCC [14]. In contrast, cyclin D1
and c-Myc appeared to be overexpressed in almost all HCCs
compared to non-tumor controls.
We next investigated protein expressions related to Wnt
signaling in human liver cancer cell lines including THLE-3, a
normal immortalized hepatocyte cell line. High level of HDAC2
expression was detected in all tested cell lines, while b-catenin was
not detectable in HepG2, a hepatoblastoma cell line or c-Myc
expression varied in different liver cell lines (Figure 1B). These
suggest that activation of Wnt signaling and/or c-Myc may not
contribute to aberrant regulation of HDAC2 in liver cancers.
Finally, this suggestion was further validated by gene knockdown
of b-catenin, cyclin D1 and c-Myc in Hep3B cells. As expected,
HDAC2 expression was not affected by depletion of b-catenin,
cyclin D1 or c-Myc in Hep3B cells (Figure 1C). These results
indicated that aberrant regulation of HDAC2 is not dependent on
Wnt pathway or c-Myc activation in liver tumorigenesis.
Targeted-disruption of HDAC2 elicits anti-mitogenic
effects on HCC
We next investigated that HDAC2 represented major histone
deacetylase activity among the HDACs in HCC. We assessed the
endogenous expression levels of various HDACs in Hep3B cells by
using qRT-PCR with specific primer for each HDAC (Table S3).
HDAC2 resulted in the highest expression level among the
analyzed HDACs (Figure 2A). In addition, HDAC2 depletion
caused accumulation of acetylated histones H3 and H4 indicating
a major deacetylase activity in Hep3B cells (Figure 2B).
Figure 1. Overexpression of HDAC2 is not regulated by Wnt signaling in human HCC. (A) Tissue lysates were prepared from non-tumoral
liver tissues (N) or tumors (HCC, HBV-positive, Edmondson grade G3) (T) and immunoblotted with indicated antibodies. (B) Protein expressions of
HDAC2, b-catenin and c-Myc were also determined by immunoblotting in human liver cancer cell lines. (C) Hep3B cells were transfected with siRNAs
targeting b-catenin, cyclin D1 or c-Myc. The protein level of HDAC1 or 2 was assessed by immunoblotting. A typical result from three performed
experiments is shown.
doi:10.1371/journal.pone.0028103.g001
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expression of HDAC2 in hepatocarcinogenesis, HDAC2 expres-
sion was abrogated by small interfering RNA (siRNA) directed
against HDAC2. The growth rate of cells transfected with HDAC2
siRNA was significantly regressed compared to non- (None) or
scrambled siRNA transfectants (Scr) (Figure 2C). To generalize this
finding to liver cancer cells, we employed three more different liver
cancer cell lines and investigated the tumor suppressing effects of
HDAC2-targeting upon tumor cell growth. Among liver cancer cell
lines, we selected HepG2, SNU-182 and SNU-449 cell lines as they
exhibited relatively high expression for HDAC2 in Western blot
analyses (Figure S2A). Then, each cell line was transfected with
HDAC2 siRNA. As shown in Figure S2B, the growth rate of
HDAC2 knockdown cells appeared to be significantly regressed as
compared to control (None or control siRNA transfectant) cells.
Concordant with previous observation in Hep3B cells, all cell lines
displayed significant growth retardation upon HDAC2-targeting.
These results strengthen our suggestion that aberrant overexpression
of HDAC2 contributes mitotic potential during liver tumorigenesis.
The anti-growth effect of HDAC2 depletion in HCC cells could be
partially explained by the intervention of cell growth regulation such
as cellular apoptosis, cell cycle arrest or cellular senescence. Thus,
we next explored the effects of HDAC2 suppression on cellular
apoptosis and cell cycle regulation. Flow cytometric analysis for
measuring Annexin V stained cells showed no significant induction
of apoptotic cells compared to control (Scr siRNA) (Figure 2D, left
panel). In addition, HDAC2 depletion did not affect expressions of
pro-apoptotic components such as AIF, Bax and Apaf-1, nor did it
cause caspase-3 or PARP cleavage (Figure 2D, right panel). These
results indicated that overexpression of HDAC2 did not affect the
apoptotic signal in liver tumorigenesis.
We then investigated if HDAC2 depletion causes anti-mitogenic
effect in HCC cells. As shown in Figure 3A, de novo DNA synthesis
was significantly inhibited by HDAC2 depletion at both 48 and
72 h post-transfection of HDAC2 siRNA compared to control in
thymidine incorporation assay. This anti-proliferative effect of
Figure 2. Effects of HDAC2 inhibition on the cell growth and apoptosis. (A) Endogenous expression of HDACs (HDAC1-8) in Hep3B cells by
qRT-PCR. Each HDAC mRNA level was normalized against GAPDH. (B) HDAC2 was depleted by HDAC2 specific siRNA in Hep3B cells. To ascertain the
knockdown efficiency and suppression of HDAC activity, protein expressions of HDAC2, acetyl-histone H3 and H4 were determined by
immunoblotting. (C) Time course analysis of the effect of HDAC2 inhibition on adherent cell number. The cell counts show the results of four
independent experiments, expressed as mean 6 SD (* p,0.05 relative to Scr siRNA). (D) After 48 h transfection of HDAC2 siRNA, cells were stained
with Annexin V-FITC and propidium iodide, and apoptotic cells were analyzed by flow cytometric analysis (left). Protein expressions of the
proapoptotic genes (AIF, Bax, Apaf-1, cleaved-caspase3, cleaved-PARP) were also determined by immunoblotting (right).
doi:10.1371/journal.pone.0028103.g002
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HDAC inhibitor, VPA on Hep3B cells (Figure 3A). We then
performed cell cycle analysis of PI-stained cells in HDAC2 siRNA
transfectants using flow cytometry. HDAC2 depletion led to an
increase in G1 phase by 12.8% with a concomitant decrease in S
phase and G2/M phase by 5.3% and 7.8% respectively at 48 h
after transfection (Figure 3B). VPA also appeared to induce cell
cycle arrest in G1 phase with strong activation of p21
WAF1/Cip1
expression in Hep3B cells (Figs. 3C and 3D). Similarly, HDAC2
depletion also caused induction of p21
WAF1/Cip1 expression in
Hep3B cells. However, interestingly, we found that HDAC2
depletion also suppressed cyclin-dependent kinase 2 (CDK2)
expression, but VPA did not in Hep3B cells (Figure 3D).
Selective regulation of HDAC2 on G1/S components of
cell cycle circuitry in Hep3B cells
The fact that the suppression of HDAC2 caused cell cycle arrest
in G1 phase implies that HDAC2 can modulate activities of cell
cycle regulating components. Therefore, we examined the effects
of HDAC2 depletion on the regulatory components of G1/S cell
cycle transition. In G1/S transition, it has been well established
that negative cell cycle regulators such as p15
INK4B, p16
INK4A,
p18
INK4C, p19
INK4D, p27
Kip1 and p21
WAF1/Cip1 are the key
modulators that suppress cyclin D1/CDK4, 6 or cyclin E/CDK2
complexes [15].
When these cell cycle modulators were examined, p16
INK4A and
p21
WAF1/Cip1 were selectively induced by HDAC2 depletion
in Hep3B cells. In addition, HDAC2 depletion also elicited
concomitant suppression of cyclin D1, CDK4 and CDK2,
respectively (Figure 4A). These results strongly suggest that
HDAC2 overexpression causes the suppression of the negative
cell cycle modulators such as p16
INK4A and p21
WAF1/Cip1, and at
the same time, induces the expression of their specific regulators
such as cyclin D1, CDK4 and CDK2 in the G1/S transition of
Hep3B cells.
In general, activated cyclin/CDK complex can cause hyperpho-
sphorylation of pRb which loses its tumor suppressor activity, and
which allows for E2F/DP1 transcriptional activity. Thus, we next
investigated whether the dysregulation of cyclins and CDKs by
HDAC2 affects the E2F/DP1 transcriptional activity. As expected,
HDAC2 suppression caused hypophosphorylation of p130, a pRb
isoform (Rb2) in Hep3B cells (Figure 4B). This result implies that
Figure 3. Effects of HDAC2 inhibition on the proliferation and the cell cycle progression of HCC cells. (A) Cell proliferating activity was
assessed by thymidine incorporation analysis in Hep3B cells after transfection with HDAC2 or scrambled siRNA. At 48 and 72 post-transfection, [
3H]-
thymidine incorporation was analyzed by scintillation counting. The results represent the mean 6 SD of three experiments (* p,0.01). (B) After 48
and 72 h post-transfection of HDAC2 siRNA, the DNA content of PI-stained cells was analyzed by flow cytometry. (C) After 1 mM Valproic acid
treatment to Hep3B cells for 72 h, the DNA content of PI-stained cells was analyzed by flow cytometry. (D) Hep3B cells were transient transfected
with HDAC2 or scrambled siRNA (100 nM) for 72 h, and 1 mM of Valproic acid was also treated on Hep3B cells for 72 h. The protein expressions of
p21
WAF1/Cip1 and CDK2 were determined by immunoblotting. Three experiments with the same results were performed.
doi:10.1371/journal.pone.0028103.g003
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protein via transcriptional activation of cyclin/CDKs and/or
inactivation of negative modulators. This suggestion was support-
ed by the fact that the E2F/DP1 target genes such as E2F1,
PCNA, CDC2 and E2F5 were selectively down-regulated by
HDAC2 depletion (Figure 4B). This systemic regulation on cell
cycle components was validated in 10 paired HCC tissues. As a
result, p21
WAF1/Cip1 expression was detected at relatively high
levels in all non-tumor tissues, but it was greatly reduced or non-
detectable in all HCC tissues. In contrast, CDK2 and PCNA
appeared to be up-regulated in all HCC tissues compared to non-
tumor tissues (Figure 4C).
These results indicate that HDAC2 inactivation may cause
comprehensive gene expression changes of genetic elements that
associate with mitotic activity of tumor cells. Thus, to identify the
molecular signature that may affect tumor cell growth, we
employed and performed large-scale gene expression analysis on
HDAC2 knockdown cells (Hep3B-shHDAC2) and compared with
its corresponding control (Hep3B-mock) by using whole genome
expression microarray. From this, we could identify large number
genetic elements that are differentially expressed by HDAC2
inactivation in Hep3B cells. Among these, we recapitulated genes
that are associated with cell cycle regulation, and depicted
their differential gene expressions as heat map and bar graphs
(Figure 5A). As shown in Figure 5A, we could confirm HDAC2
inactivation by detecting very low endogenous HDAC2 expression
level among HDACs and sirtuins (left panel). We also observed up-
regulation of some negative cell cycle regulators such as CDKN1A
(p21
WAF1/Cip1), CDKN2C (p18
INK4C), CDKN3 genes, and simulta-
neously, down-regulation of some CDKs and cyclin genes and
E2F/DP1 target genes such as CDC25C, PCNA and E2F1
(Figure 5A, right panel). These results are consistent with the
results in Figure 4 that show systemic modulation of cell cycle
proteins by HDAC2 via Western blot analysis in Hep3B cells.
Further, to validate gene expression data of microarrays and to confirm
transcriptional levels of differentially expressed genes, we performed
quantitative real-time PCR (qRT-PCR) for HDAC2, CDKN1A
(p21
WAF1/Cip1), CDKN2A (p16
INK4A), CDK2 and PCNA genes
(Figure 5B). As shown in Figure 5B, Hep3B-siHDAC2 cells exhibited
very low endogenous HDAC2 expression. With this condition, we
were able to confirm that both CDKN1A (p21
WAF1/Cip1)
and CDKN2A (p16
INK4A) were significantly up-regulated in time
dependent manner. Inversely, CDK2 and PCNA were appeared to be
down-regulated by HDAC2 inactivation. These results support our
Figure 4. Systemic modulation of regulatory components by HDAC2 in G1/S cell cycle transition. Hep3B cells were transfected with no
siRNA (None), oligofectamine only (Reag), 100 nmol/L scrambled siRNA (Scr) or 100 nmol/L of two different HDAC2 specific siRNAs (#1 and #2), and
were harvested at 72 h post-transfection. (A) Immunoblotting of CDKs, cyclins and CDK inhibitors of G1/S transition were performed. (B) Effects of
HDAC2 depletion on pRb and E2F/DP1 target gene expressions. (C) Protein expressions of p21
WAF1/Cip1, CDK2 and PCNA in human HCC tissues were
analyzed by immunoblotting. All experiments were repeated three times with same results.
doi:10.1371/journal.pone.0028103.g004
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recapitulated for HDAC family and cell cycle regulation, and graphical representation of the expression changes of genes functionally involved in
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INK4A and p21
WAF1/Cip1
and induction of CDK2, CDK4 and cyclin D1 expression by HDAC2
may exert a very potent mitotic stimulation causing uncontrolled cell
growth during HCC progression.
Sustained suppression of HDAC2 attenuates tumorigenic
potential of Hep3B HCC cells in vitro and in vivo
Since our results suggest that transient knockdown of HDAC2
exerts potent anti-tumor activity, we next investigated if sustained
suppression of HDAC2 can attenuate tumorigenic potential of
HCC cells in vitro and in vivo. For the analyses of experimental
tumorigenesis, Hep3B cells that carrying minimal expression of
HDAC2 was established by transfection of HDAC2 shRNA
(Hep3B_HDAC2KD). The functional inactivation of HDAC2 was
validated by the confirmation of selective induction of p16
INK4A
and p21
WAF1/Cip1, and suppression of CDK2, cyclin D1 and
PCNA in Hep3B_HDAC2KD cells (Figure 6A).
Then, we assessed the growth rate of Hep3B_HDAC2KD cells,
and observed that Hep3B_HDAC2KD cells exhibited reduced
growth rate compared to Hep3B_Mock or Hep3B mother cell line
(Figure 6B, p,0.05). We also investigated cell cycle analysis with
the established cell lines. For a more precise analysis of cell cycle
progression, the established cell lines were treated with nocodazole
to synchronize all the cells in G2/M phase. We then analyzed the
proportion of G1 phase cells after release from the nocodazole
block. We observed that the proportion of G1 phase cells (2n) in
Hep3B_HDAC2KD were increased at all time points after release
compared to the control (Hep3B_Mock) (Figure 6C). These results
demonstrate that the proliferative defect and/or growth retarda-
tion of Hep3B cells by HDAC2 depletion is contributed by specific
G1 arrest in cell cycle regulation.
We next performed in vitro colony formation assay, and found
that the sustained suppression of HDAC2 led to the reduced clonal
cell growth (Figure 6D, p,0.05). Finally, to demonstrate that the
aberrant regulation of HDAC2 contributes to the oncogenic
property of cells in vivo, we subcutaneously injected these cell lines
into SCID mice. The overall tumor growth was significantly
reduced in Hep3B_HDAC2KD (Figure 6E, p,0.05). The average
tumor volume at sacrifice was much smaller in the group injected
with Hep3B_HDAC2KD than Hep3B_Mock cells (Figure 6F,
p,0.05). For tumor incidence, Hep3B_Mock cell line group bore
5 tumors in all 5 injected animals, but Hep3B_HDAC2KD cell
line group exhibited 3 tumors in 5 injected animals.
HDAC2 regulates p21
WAF1/Cip1 transcriptional activity via
Sp1-binding site enriched proximal region of p21
WAF1/Cip1
promoter
Several studies have shown that HDAC inhibitors strongly
activate the expression of p21
WAF1/Cip1 through enhanced histone
acetylation of p21
WAF1/Cip1 promoter including Sp1-binding site,
which releasing the repressor HDAC from its binding [16,17].
Our present data also indicate that p21
WAF1/Cip1 is induced by
HDAC2 inactivation in Hep3B cells (Figure 3D, 4A and 5B). This
implies that histone deacetylase activity is required to suppress
p21
WAF1/Cip1 transcription activity. Therefore, to investigate
whether HDAC2 selectively regulates p21
WAF1/Cip1 expression
through the Sp1-binding site, we performed the reporter assay
with reporter constructs described in materials and methods.
Firstly, wild-type p21
WAF1/Cip1 reporter construct was trans-
fected into Hep3B_HDAC2KD cells, and its activity was
compared with that of Hep3B_Mock (left two columns in
Figure 7A, p,0.05). The Hep3B_Mock cells were also treated
with Apicidin, a HDAC inhibitor, as a positive control for
induction of p21
WAF1/Cip1 transcription (right two columns). The
Hep3B_HDAC2KD cells exhibited significant induction of
luciferase activity compared with Hep3B_Mock. Inversely, ectopic
expression of HDAC2 to Hep3B_HDAC2KD cells resulted in the
suppression of p21
WAF1/Cip1 transcriptional activity compared with
control (Figure 7B, p,0.05). These results imply that the endogenous
expression of p21
WAF1/Cip1 is selectively regulated by HDAC2 at the
transcription level in Hep3B cells. Next, to validate this implica-
tion, we performed chromatin immunoprecipitation assay with
quantitative PCR (ChIP-qPCR) for indicated p21
WAF1/Cip1
promoter region (Figure 7C and 7D). From this, we found that
HDAC2 is associated with the proximal region of the p21
WAF1/Cip1
promoter(regionDinFigure7C).Thisresultwasfurthervalidatedby
ChIP-qPCR analysis with the same promoter region of p21
WAF1/Cip1
(region D) that the acetylation status of histone H3 and/or H4 is
enhanced by targeting of HDAC2 (Figure 7E). Additionally, as there
are enriched Sp1-biding sites in region D, we next investigated
whether HDAC2 suppresses p21
WAF1/Cip1 expression via Sp1-
binding sites on the p21
WAF1/Cip1 promoter. We found that
Hep3B_HDAC2KD cells exhibited increased luciferase activity in
the presence of Sp1-binding sites, at least containing Sp1-3 to Sp1-6
(pWWP, pWPdel-BstXI and pWP101). However, p21
WAF1/Cip1
transcription activity was not induced by mutant forms of Sp1-5,6
(pWPmt-Sp1-5,6) in Hep3B_HDAC2KD cells. Interestingly,
p21
WAF1/Cip1 transcription was still induced by two mutant plasmids
(pWPdel-SmaI and Sp1-luc) having two or three tandem repeats of
Sp1-binding site near the TATA box or transcription start site.
Collectively, these results suggest that Sp1-binding site enriched on
the proximal region of p21
WAF1/Cip1 promoter are expected to be an
important site regulating p21
WAF1/Cip1 transcription by HDAC2 in
Hep3B cell (Figure 7F, p,0.05).
Discussion
Accumulating evidences has suggested that HDACs regulate the
expression and activity of numerous proteins involved in both
cancer initiation and progression [1,4]. Furthermore, several
studies have shown that certain HDAC families are aberrantly
expressed in tumors and have redundant function in cancer
development [3,18]. Consistently, targeted-disruption of HDAC2
elicited growth arrest and apoptosis of certain human cancer cells
[7,9,19,20,21,22]. However, there was no investigation about the
role of HDAC2 in liver tumorigenesis until now.
Thus, we assessed HDAC2 expression in a subset of human
HCC tissues. From this, we found that HDAC2 is deregulated and
overexpressed in all the 10 selected HCCs (Figure 1). Moreover,
we confirmed the aberrant expression of HDAC2 in randomly
selected another 20 pairs of HCCs (Figure S3). This implies that
the deregulation of HDAC2 may be required for initiating and/or
developing HCC. With this result, the former report suggesting
that the activation of Wnt signaling induced HDAC2 expression
and contributed to colon cancer development [7] led us to
investigate HDAC2 regulation on enhanced Wnt signaling in
HCC. However, our results revealed no association between
HDAC2 overexpression and Wnt signaling. This suggests that
HDAC gene families (left) and cell cycle regulation (right) by HDAC2 inactivation of Hep3B cells. (B) Validation of microarray data by quantitative real-
time PCR. The relative expression level of each gene was normalized to GAPDH mRNA in the same sample. The result of four independent
experiments was shown as mean 6 SD (Student’s t-test).
doi:10.1371/journal.pone.0028103.g005
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liver cancer is not affected by Wnt pathway.
Therefore, we then abrogated HDAC2 overexpression to
explore tumorigenic functions of HDAC2 in liver tumorigenesis.
Our results demonstrated that HDAC2 inactivation caused the
suppression of tumor cell growth in various liver cancer cell lines
(Figure 2 and S2). Interestingly, although a previous study has
demonstrated that HDAC2 inhibition increased apoptosis in HeLa
cervical cancer cells [20], our results indicated that HDAC2
inactivation did not induce apoptosis, while it strongly induced
G1/S arrest in cell cycle transition.
Many previous reports have suggested that HDAC-mediated
repression of genes can cause uncontrolled cell growth as HDACs
repress the transcription of cyclin-dependent kinase inhibitors
(CDKIs), allowing continued proliferation. Our study demonstrat-
ed that HDAC2 depletion selectively induced p16
INK4A and
p21
WAF1/Cip1, thereby resulting in the inhibition of G1/S
transition of cell cycle (Figure 4A). In addition, HDAC2 inhibition
also suppressed the expression of cyclin D1/CDK4 complex and
CDK2 in Hep3B cells. Although it is not clear whether p16
INK4A
and p21
WAF1/Cip1 suppress the transcriptional activation of these
molecules or HDAC2 directly regulates them, it is obvious that this
synergistic regulation of CDK/cyclin complex and its specific
CDKI in G1/S transition suggests a potent role of HDAC2 in the
cell cycle regulation of liver tumorigenesis.
Orderly progression through the cell cycle checkpoints involves
coordinated activation of the CDKs in the presence of associated
cyclins, which phosphorylates target substrates including members
of the ‘‘pocket protein’’ family. One of these, Rb protein (pRb) is
phosphorylated sequentially by both the cyclin D1/CDK4 and
cyclin E/CDK2 complexes. Our results demonstrated that the
cooperative regulation of CDKI and its specific cyclin/CDK
complex by HDAC2 caused the hypophosphorylation status of
pRb, and as consequently, down-regulated some of E2F/DP1
target genes that may be necessary in G1/S transition (Figure 4B).
HDACs are known to function by interacting with tumor
suppressor genes such as p53, pRb and BRCA1 [23,24,25]. For
example, HDAC1 is necessary for the repression of E2F target
genes by pRb [23]. Alternatively, the deacetylation of non-histone
proteins such as p53 may also play a role in controlling the cell
cycle dynamics. Unlike this suppressive role of HDACs on pRb
and its interaction with E2F/DP transcription, our data suggest
that HDAC2 act as a potent modulator regulating the expression
level of CDK inhibitor, cyclins and CDKs in the G1/S transition.
In addition, we noted that both VPA treatment and HDAC2
depletion exerted anti-mitogenic activity through the induction of
p21
WAF1/Cip1, but had different effects on transcriptional regula-
tion of cell cycle components in Hep3B cells (Figure 3D). Indeed,
VPA treatment strongly induced p21
WAF1/Cip1 and suppressed
CDK4 expression similar to that with HDAC2 inhibition, but it
did not affect the E2F/DP1 target gene expression such as CDC2,
PCNA or E2F1 (Figure S4). In addition, from whole gene
expression microarray experiment, we were able to identify large-
number genes that were differentially expressed by HDAC2
inactivation. The molecular signature that was recapitulated as
mitotic gene elements on HDAC2 inactivation included up-
regulation of cell cycle inhibitors and down-regulation of cyclins,
CDKs and E2F/DP1 target genes (Figure 5A). This result
indicates that the targeted-disruption of HDAC2 exerts anti-
tumor activity with different spectrums of underlying mechanisms
of HDAC inhibitors.
Although there are some reports that HDAC2 expression is
dysregulated in cancer cells, only limited numbers of articles
have shown in vivo analysis of HDAC2 in cancer. In this study,
we successfully established stable cell line that sustained limited
expression of HDAC2 in Hep3B cells. This cell line (Hep3B_H-
DAC2KD) exhibited reduced tumor cell growth, retardation of
G1/S transition and loss of transforming potentials (Figs. 6A-
D). Interestingly, we also found that HDAC2 suppression
augmented cellular senescence by which might be the induction
of p16
INK4A in Hep3B_HDAC2KD cells (Figure S5). With these
in vitro anti-tumor effects of HDAC2 inhibition, we demon-
strated a remarkable suppression of tumor mass growth in vivo
and a lower tumor incidence by using these cell lines in an
experimental mouse xenograft model for cancer (Figs. 6E
and 6F).
Dysregulation of both p21
WAF1/Cip1 expression and HDAC
function are commonly observed in a variety of human cancers.
It is not clear whether HDAC overexpression leads to the
epigenetic suppression of p21
WAF1/Cip1 per se or ifotherprocesses
also support this phenomenon. However, these mechanisms are
closely interconnected, act in a synergistic manner, and offer a
growth advantage to the tumor cells. In this respect, our results
demonstratedthatthesuppressionofHDAC2inducesp21
WAF1/Cip1
via Sp1-binding site enriched proximal region of p21
WAF1/Cip1
promoter (Figure 7). Although it’s not clear that HDAC2
suppresses p21
WAF1/Cip1 through Sp1-binding site by forming a
complex with other molecules, it is clear that HDAC2
suppression causes its release from the proximal region near
the TATA box (Sp1-5,6) at the p21
WAF1/Cip1 promoter leading
to a loss of repression and an induction of transcription
(Figure 7).
In conclusion, we have demonstrated that targeted-disrup-
tion of HDAC2 revealed strong anti-proliferative effects on
human HCC in vitro and in vivo.A b e r r a n ta c t i o n so fH D A C 2
disturbed homeostasis via dysregulation of gene expressions of
cell cycle components in HCC. Here, we propose that the
aberrant regulation of HDAC2 and its epigenetic regulation of
gene transcription in cell cycle components play an important
role in the development of HCC. This may contribute to tumor
cells having mitogenic potential in the initiation and progres-
sion of HCC, thereby providing novel targets for therapeutic
intervention.
Figure 6. Sustained suppression of HDAC2 attenuates the tumorigenic potential of Hep3B cells in vitro and in vivo. (A) Confirmation of
HDAC2 suppression by its specific regulation of cell cycle components in HDAC2 depleted cell lines. A typical result of three performed experiments is
shown. (B) Time course cell counting analyses of Hep3B and two stable cell lines (Hep3B_Mock and Hep3B_HDAC2KD). The cell counts show the
results of four independent experiments. (C) HDAC2-deficient (Hep3B_HDAC2KD) or Mock (Hep3B_Mock) stable cell line was blocked in G2/M
transition by nocodazole and then released in fresh medium. The DNA content was determined by FACS analysis with PI-stained cells at each time
point (0, 2, 6, 12, 24, 48 h after release) (left). The percentage of cells in G1 phase was calculated and represented as bar graph (right). A typical result
of three performed experiments is shown. (D) In vitro Colony formation assay showed the effect of HDAC2 inhibition on the growth of cell colonies
after three weeks incubation. Quantification of colony numbers shown is mean 6 SD of three independent experiments (top). The representative
scan of 0.5% crystal violet-stained cells (bottom). (E) Tumor growth of Hep3B cell xenografts. (F) Representative tumors obtained at sacrifice after5 2
days of growth (upper left) and mice (upper right). The tumor volume at sacrifice was presented as bar graph. Values shown are mean 6 SD, n=5 for
Mock; n=3 for HDAC2KD. Data in (B, D, E and F) were analyzed by Student’s t-test. * p,0.05, Hep3B_HDAC2KD vs Hep3B_Mock.
doi:10.1371/journal.pone.0028103.g006
Dysregulation of Cell Cycle Proteins by HDAC2
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e28103Dysregulation of Cell Cycle Proteins by HDAC2
PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e28103Materials and Methods
Ethics Statement
Total thirty hepatocellular carcinoma tissues with their corre-
sponding normal were obtained from Yonsei University, School of
Medicine, Seoul, Korea. Informed consent was provided according
to the Declaration of Helsinki. Written informed consent was
obtained from all subjects, and the study was approved by Ethics
Committee of the Catholic University of Korea, College of
Medicine (IRB approval number; CUMC09U119). For animal
study, all animal experiments were performed in compliance with
the guidelines of the Institutional Animal Care and Use Committee
(IACUC) of Department of Laboratory Animal, College of
Medicine, The Catholic University of Korea (approval number;
CUMC-2009-0050-03).
Plasmid preparation
The following plasmids have previously been described:
pME18S-FLAG-HDAC2, which expresses FLAG epitope-tagged
HDAC2 [26]; a minimal luciferase reporter plasmid, Sp1-luc [27];
pWWP, which was generated by subcloning the 2.4 kbp human
wild-type p21
WAF1/Cip1 promoter into pGL3-Basic reporter
vector, and three deletion-formed plasmids (pWPdel-BstXI,
pWP101 and pWPdel-SmaI) and two mutant plasmids which
have mutation on specific Sp1 binding site (pWPmt-Sp1-3 and
pWPmt-Sp1-5,6) [28]. The pSilencer
TM3.1-H1 neo plasmid
(Ambion, Austin, TX, USA) was used for the construction of
shRNA-encoding plasmids. Two pairs of oligonucleotides were
annealed and subcloned into the vectors, respectively (Table S1).
Cell culture and siRNA transfection
Human HCC cell line HepG2 (wt p53), Hep3B (p53 null),
PLC/PRF/5 (mt p53) and immortalized liver cell lines (Chang
and THLE-3) were obtained from the ATCC (Manassas, VA,
USA). The SNU-449 cell line, which harbors p53 mutation at
exon 5, was also purchased from the Korean Cell Line Bank
(KCLB). siRNA transfection was performed with Oligofectamine
or Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Hep3B cells were transfected
with validated human b-catenin, c-Myc, cyclin D1 or two pre-
designed HDAC2 siRNAs (Table S2) (Ambion) at a final
concentration of 100 nM. Scrambled siRNA were also purchased
and used as a control.
Stable expression of HDAC2 shRNA
Cells were transfected with 1 ug of HDAC2-shRNA Expression
vector, pSilencer-HDAC2-#1 or pSilencer-HDAC2-#2. At 48 h
post-transfection, Geneticin (G418 from Invitrogen) was added to
the medium (0.5 mg/mL), and G418-resistant colonies were
selected. The medium was changed every 2 days. About 3 weeks
later, the G418-resistant cells were isolated as single colonies and
separately expanded.
qRT-PCR
Total RNA was isolated by using TRIzol (Invitrogen) as
described by the manufacturer. cDNA was generated by
Transcriptor First Strand cDNA Synthesis Kit (Roche Applied
Science, Indianapolis, IN, USA). Relative levels of specific mRNA
were determined with a SYBR Green chemistry system. All PCRs
were performed with the iQ
TM5 Real-Time PCR Detection
System (Bio-Rad Laboratories, Philadelphia, PA, US) according to
the manufacturer’s instruction. The GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) gene was used as a control gene for
normalization. PCR primers used were listed in Table S3.
Western blotting
Cells were lysed using RIPA buffer (25 mM Tris-HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
100 mg/mL PMSF, 1 mg/mL aprotinin and 0.5% sodium orthova-
nadate). SDS-PAGE and immunoblotting were subsequently
performed. Antibodies used were listed in Table S4. The ECL
reagent was used and chemiluminescence detected (GE Healthcare).
Cell growth assay
Trypan blue dye exclusion assay was used to determine the
number of viable cells present in a cell suspension. One part of the
cell suspension was mixed with one part of 0.4% trypan blue
solution, and allowed to incubate at room temperature for 3 min.
The trypan blue/cell mixture was then applied to a hemocytom-
eter, and unstained (viable) and stained (non-viable) cells were
counted separately using binocular microscope. 3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
says were also conducted to measure the relative number of viable
cells. At indicated time points, medium was replaced with the fresh
medium supplemented with MTT (0.5 mg/ml) (Sigma-Aldrich,
St. Louis, MO, USA). Absorbance was measured using a
multilabel plate reader (VICTOR3
TM, PerkinElmer, Bridgeport
Avenue Shelton, CT, USA) at a wavelength of 570 nm.
Experiments were repeated at least three times.
Cell proliferation assay
Thymidine incorporation was determined using [methyl-
3H]-
thymidine (New England Nuclear Life Science). Briefly, after
Figure 7. HDAC2 regulates p21
WAF1/Cip1 transcription via Sp1-binding sites in the p21
WAF1/Cip1 promoter. (A) HDAC2-deficient
(Hep3B_HDAC2KD) or Mock stable cell line (Hep3B_Mock) was transfected with a reporter construct containing the human wild-type p21 promoter
(22326 to +1) linked to a luciferase reporter gene (pWWP-Luc). For the positive control, 1 mM of Apicidin was treated on the mock cell line for 24 h
and luciferase activity was measured. The luciferase activity from the mock cells transfected with pGL3 basic vector was arbitrarily defined as 1.0. (B)
Ectopic expression of HDAC2 suppressed the p21
WAF1/Cip1 transcriptional activity. HDAC2-deficient stable cell line (Hep3B_HDAC2KD) was transfected
with FLAG-epitope tagged HDAC2 expression vector (F-HDAC2) or control vector (Con). After 24 h incubation, pWWP-Luc vector was also transfected.
The promoter activity was measured and normalized as mentioned above. (C) A schematic of the p21
WAF1/Cip1 promoter depicting the regions
analyzed by ChIP-qPCR (black bars, A-D). (D) The association of HDAC2 in the p21
WAF1/Cip1 promoter was assessed by the amplification of each region
immunoprecipitated with HDAC2. The amount of DNA precipitated by either anti-HDAC2 or control IgG was expressed as percentage of the total
input genomic DNA. The result of four independent experiments was shown as mean 6 SD. (E) Acetylations of histone H3 and H4 associated with the
proximal p21
WAF1/Cip1 promoter was increased by inhibiting association of HDAC2. Hep3B cells were transiently transfected with control (Con) or
HDAC2 siRNA for 48 h and subjected to ChIP-qPCR analysis using acetyl-histone H3 (anti-Ac-H3) and H4 (anti-Ac-H4) antibody or control IgG.
Precipitated genomic DNA was amplified for the proximal promoter of the p21 locus (region D represented in Figure 7C) by real-time PCR. The
amount of precipitated DNA was expressed as percentage of the total input genomic DNA. The result of three independent experiments was shown
as mean 6 SD. (F) The indicated constructs, pWWP, pWPdel-BstXI, pWP101, pWPmt-Sp1-3, pWPmt-Sp1-5,6, pWPdel-SmaI and Sp1-luc were
transiently transfected into each Hep3B stable cells. The promoter activity was measured, and fold induction by HDAC2 depletion is calculated. On
the left, the scheme of each construct was shown. Data in (A, B and F) were analyzed by Student’s t-test. * p,0.05.
doi:10.1371/journal.pone.0028103.g007
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3H]-thymidine (1 mCi/
mL) was added to the culture media 10 h prior to each analysis. At
48 and 72 h post-transfection, the cells were washed with PBS and
5% TCA, and lysed using lysis buffer (0.5 M NaOH, 2% SDS).
Aliquots were used to determine thymidine incorporation on a
scintillation counter LS6500 (Beckman Coulter, Fullerton, CA,
USA).
Detection of apoptotic cells
Quantification of apoptotic cells was performed using Annexin
V-FITC Apoptosis Detection Kit according to the manufacturer’s
specifications (BD Biosciences, San Jose, CA, USA). Cells were
analyzed using FACSCalibur flow cytometry and CellQuest
TM
software (BD Biosciences) to determine the percentage of
apoptosis.
Cell cycle analysis
Cells were trypsinized, washed with cold PBS, and fixed in pre-
chilled 70% ethanol at 220uC overnight. For measurement of
DNA content, cells were stained with Propidium Iodide (PI)
solution (50 mg/mL PI, 100 mg/mL RNase A, 0.05% Triton X-
100 in PBS), and incubated at 37uC in the dark for 30 min. DNA
content was examined by flow cytometry using FACSCalibur (BD
Biosciences) with FlowJo software (Tree Star).
Microarray analysis
For the large-scale gene expression profiling, HDAC2 gene
silencing was performed by transfecting Hep3B cells with HDAC2
shRNA expression plasmids for 48 hours as described above.
Total RNA was extracted from three independent sets of
experiments using TRIzol Reagent (Invitrogen), followed by clean
up on Ambion columns (Illumina Total-Prep RNA Amplification
Kit, Ambion). For each experimental condition, an RNA pool was
obtained by mixing equal quantities of total RNA from each of the
three independent RNA extractions. RNA quality control was
performed with Experion
TM system (Bio-Rad). Microarray
analysis was performed by using HumanHT-12 V4 Expression
BeadChip (Illumina, Inc., San Diego, CA). Biotinylated cRNA was
prepared by using the MessageAmp kit (Ambion, Inc., Austin,
TX). Hybridization and scanning of the chips were performed
according to the standard protocol (Illumina). The primary
microarray data are available in the GEO database (GSE32070).
Cell synchronization
Stable cell lines were synchronized in prometaphase by
treatment with 100 ng/mL nocodazole for 18 h, and then released
from the drug-induced cell cycle arrest. After three washes with
PBS, cells were cultured in fresh medium for different times as
indicated in the experiment.
Clonogenic assay
Clonogenic cell growth in vitro was assessed according to the
previously described method [29]. Briefly, each cell line (Mock or
HDAC2 knockdown Hep3B cells) was seeded in 6-well plate (1000
cells/well). After two weeks, colonies are fixed with formaldehyde
(1.0% v/v) for 30 min at room temperature, and stained with
crystal violet (0.5% w/v). The stained colonies were counted by
using the clono-counter software [30].
Tumor xenograft experiments
For xenograft tumorigenesis assay, 5610
6 cells of the indicated
cell lines were suspended with 0.2 mL PBS (pH 7.4) and mixed
with 20% (v/v) Matrigel. Cell suspensions were subcutaneously
inoculated in 5 week-old SCID mice. Tumor size (V) was
calculated weekly, using the formula, V (mm
3) =0.526(width)
26
(length).
ChIP-qPCR analysis
Chromatin preparation was performed by using Chromatin
prep module (Pierce, Rockford, IL, USA). In brief, freshly
prepared 16% formaldehyde was added to the cells (2610
6
cells/ChIP reaction) at a final concentration of 1%. Cells were
incubated at room temperature for 10 min, then excess formal-
dehyde was quenched by addition of glycine (0.5 M). After
washing twice, the cells were scraped into 1 ml cold PBS
containing 16 Halt Cocktail. The cells were pelleted and then
resuspended in 100 ml of Lysis Buffer 1 containing 16 Halt
cocktail. Nuclei were isolated and resuspended in MNase
Digestion Buffer containing 1 mM DTT. Cross-linked DNA was
digested with 0.25 ml of Micrococcal Nuclease (10 U/ml) at 37uC
for 15 min yielding fragments from 200 to 1000 bp and
centrifuged at 9,0006g to recover the nuclei. Digested chromatin
was resuspended in 50 ml of Lysis Buffer 2, and 5 ml of each was
reserved as the 10% total input. Chromoatin immunoprecipitation
(ChIP) assay was carried out using Pierce Agarose ChIP kit (Pierce)
following manufacturer’s protocol. For each IP, diluted chromatin
was incubated with antibodies specific for HDAC2, Ac-histone H3
and Ac-histone H4 (Cell signaling, Lake Placid, NY, USA) or
normal rabbit IgG at 4uC for 2 h or overnight. Each immuno-
precipitated complex was column purified using the agarose resin,
and eluted in 150 ml of IP Elution Buffer for 30 min at 65uC with
shaking. Reverse cross-linked DNA was purified by using DNA
Clean-up Column according to manufacturer’s instruction. 5 mlo f
each of the purified DNA was used as template for 60 cycles of
PCR amplification using designated primers (Table S3).
Luciferase assay
Cells (1.5610
5 cells/well) were transfected with 500 ng/well of
p21
WAF1/Cip1 promoter reporter plasmid using Lipofectamine
PLUS (Invitrogen). At 24 h post-transfection, the medium was
changed to a medium with or without 1 mM apicidin. After 24 h of
incubation, the activities of luciferase were measured using Dual-
Luciferase Reporter Assay System (Promega, Madison, WI, USA).
Statistical analyses
All experiments were performed three times at least, and
samples were analyzed in triplicate. Results were presented as
mean (SD). The statistical difference between groups was assessed
by applying Student’s t-test for unpaired data, using Microsoft
Office Excel (Microsoft, Albuquerque, NM, USA).
Supporting Information
Figure S1 Expression of HDAC2 in hepatocelluar carci-
noma (HCC) defined by gene expression profiling (GEP).
Analysis by gene expression profiling (GEP) data of HDAC2
expression in patients corresponding to low-grade dysplastic
nodule (LGDN), high-grade dysplastic nodule (HGDN) and
HCC patients (Edmondson grade G1-3). HDAC2 overexpression
was observed with significance in high grade tumor (Edmondson
grade G3) (p,0.01).
(TIF)
Figure S2 HDAC2 inactivation causes growth retarda-
tion in liver cancer cell lines. (A) The expression levels of
HDAC2 protein in liver cancer cell lines. Total protein extracts
were prepared from the indicated cell lines, and were examined by
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HDAC2 causes growth retardation of HCC cell lines. Cell viability
was determined by MTT assay in the indicated cell lines
transfected with either control or HDAC2 siRNA. Cell prolifer-
ation was determined by measuring the absorbance at A570 using
MTT solution at the indicated time after transfection. Data are
expressed as mean 6 SD (* p,0.05, ** p,0.01). All measure-
ments were performed in triplicate, and each experiment was
repeated at least two times.
(TIF)
Figure S3 HDAC2 expression is aberrantly overex-
pressed in human HCC. Human HCC tissue lysates were
prepared from non-tumoral liver tissues (N) or tumors (HCC, HBV-
positive, Edmondson grade G3) (T) and immunoblotted with HDAC2
antibody. Cell lysates from Hep3B was used as positive control for
HDAC2 expression. The GAPDH was used as a loading control.
(TIF)
Figure S4 Effects of Valproic acid (VPA) on regulatory
components of G1/S cell cycle transition in Hep3B cells.
After 48 hours of VPA treatment to the Hep3B cells at indicated
concentrations, cells were harvested and subjected for immuno-
blotting. The GAPDH was used as a loading control, and a typical
result of two performed experiments is shown.
(TIF)
Figure S5 Sustained suppression of HDAC2 increases
cellular senescence of Hep3B cells. Two stable cell lines
(Hep3B_Mock and Hep3B_HDAC2KD) were seeded in 60 mm
dish (5610
5 cells/well). On the next day, cells were fixed and
stained for SA (senescence activated)-b-galactosidase expression
using the Senescence Detection kit (Biovision) according to the
manufacturer’s instructions. Cells were incubated with the SA-b-
galactosidase staining solution for 16 hours at 37uC. The staining
solution was removed and representative images were acquired on
a microscope with a CCD camera. Arrows indicate strong positive
cells for SA-b-galactosidase staining. Representative images of
Hep3B_Mock (left) and Hep3B_HDAC2KD (right) were shown.
(TIF)
Table S1 Oligonucleotide sequence for HDAC2 shRNA
plasmid construction.
(XLS)
Table S2 HDAC2 siRNA sequences used in this study.
(XLS)
Table S3 Primer information in this study.
(XLS)
Table S4 Antibodies used for immunoblotting.
(XLS)
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